MX2019009347A - Oligonucleotidos multimericos con menor eliminacion en el riñon. - Google Patents

Oligonucleotidos multimericos con menor eliminacion en el riñon.

Info

Publication number
MX2019009347A
MX2019009347A MX2019009347A MX2019009347A MX2019009347A MX 2019009347 A MX2019009347 A MX 2019009347A MX 2019009347 A MX2019009347 A MX 2019009347A MX 2019009347 A MX2019009347 A MX 2019009347A MX 2019009347 A MX2019009347 A MX 2019009347A
Authority
MX
Mexico
Prior art keywords
multimeric oligonucleotides
oligonucleotides
kidney clearance
multimeric
decreased kidney
Prior art date
Application number
MX2019009347A
Other languages
English (en)
Inventor
Hadwiger Philipp
Peter Vornlocher Hans-
Miles Brown Jonathan
K H Neuman Kristin
Original Assignee
Mpeg La Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mpeg La Llc filed Critical Mpeg La Llc
Publication of MX2019009347A publication Critical patent/MX2019009347A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3519—Fusion with another nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3533—Halogen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/51—Physical structure in polymeric form, e.g. multimers, concatemers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/53—Methods for regulating/modulating their activity reducing unwanted side-effects

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a métodos para administrarle a un sujeto oligonucleótidos multiméricos que tienen subunidades monoméricas unidas mediante enlazadores. Los oligonucleótidos multiméricos tienen un peso molecular de al menos alrededor de 45 kD y otras características, tal como la reducción de su eliminación debida a filtración glomerular. La presente invención se refiere, además, a tales oligonucleótidos multiméricos y métodos para sintetizar tales oligonucleótidos multiméricos.
MX2019009347A 2017-02-06 2018-02-06 Oligonucleotidos multimericos con menor eliminacion en el riñon. MX2019009347A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762455231P 2017-02-06 2017-02-06
US201762522363P 2017-06-20 2017-06-20
US201762561853P 2017-09-22 2017-09-22
PCT/US2018/017062 WO2018145086A1 (en) 2017-02-06 2018-02-06 Multimeric oligonucleotides having decreased kidney clearance

Publications (1)

Publication Number Publication Date
MX2019009347A true MX2019009347A (es) 2019-10-07

Family

ID=63039118

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019009347A MX2019009347A (es) 2017-02-06 2018-02-06 Oligonucleotidos multimericos con menor eliminacion en el riñon.

Country Status (11)

Country Link
US (2) US11078484B2 (es)
EP (1) EP3576752A4 (es)
JP (1) JP7183167B2 (es)
KR (2) KR102623311B1 (es)
CN (1) CN110248665A (es)
AU (1) AU2018215684B2 (es)
CA (1) CA3051480A1 (es)
IL (2) IL267806B2 (es)
MX (1) MX2019009347A (es)
SG (1) SG11201906728TA (es)
WO (1) WO2018145086A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101141544B1 (ko) 2009-03-13 2012-05-03 한국과학기술원 에스아이알엔에이 다중 접합체 및 이의 제조방법
CN108026527B (zh) 2015-06-15 2022-05-10 Mpeg La有限责任公司 确定的多偶联寡核苷酸
US20230287406A1 (en) * 2019-03-04 2023-09-14 Mpeg La, L.L.C. Multimeric oligonucleotides with enhanced bioactivity
US20200385737A1 (en) * 2019-03-29 2020-12-10 University Of Massachusetts OLIGONUCLEOTIDE-BASED MODULATION OF C9orf72
EP3966328A4 (en) 2019-05-06 2023-10-18 University Of Massachusetts ANTI-C9ORF72 OLIGONUCLEOTIDES AND RELATED METHODS
JP2022543191A (ja) * 2019-07-30 2022-10-11 エムペグ エルエイ リミテッド ライアビリティ カンパニー 増強された生理活性を有する多量体オリゴヌクレオチドの皮下送達
WO2021026476A1 (en) * 2019-08-08 2021-02-11 Mpeg La, L.L.C. Complement targeting with multimeric oligonucleotides
WO2021222635A2 (en) * 2020-04-30 2021-11-04 Mpeg La, L.L.C. Multimeric oligonucleotides with divided strands

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9207381D0 (en) 1992-04-03 1992-05-13 Ici Plc Synthesis of oligonucleotides
AU2003282722A1 (en) 2002-10-02 2004-04-23 Alnylam Pharmaceuticals Inc. Therapeutic compositions
EP3450559A1 (en) 2003-03-07 2019-03-06 Alnylam Pharmaceuticals, Inc. Therapeutic compositions
US8969543B2 (en) 2003-04-03 2015-03-03 Bioneer Corporation SiRNA-hydrophilic polymer conjugates for intracellular delivery of siRNA and method thereof
EP1608735A4 (en) 2003-04-03 2008-11-05 Alnylam Pharmaceuticals RNAI CONJUGATES
CA2521464C (en) 2003-04-09 2013-02-05 Alnylam Pharmaceuticals, Inc. Irna conjugates
KR20060015505A (ko) 2003-04-13 2006-02-17 엔존 파마슈티컬즈, 인코포레이티드 올리고뉴클레오타이드 전구약물
EP1625138A4 (en) 2003-04-17 2010-06-23 Alnylam Pharmaceuticals Inc PROTECTED MONOMERS
US7851615B2 (en) 2003-04-17 2010-12-14 Alnylam Pharmaceuticals, Inc. Lipophilic conjugated iRNA agents
DK1620544T3 (en) 2003-04-17 2019-01-14 Alnylam Pharmaceuticals Inc MODIFIED iRNA AGENTS
US20100170000A9 (en) 2004-10-25 2010-07-01 Devgen Nv Rna constructs
AU2006275579B2 (en) 2005-08-01 2012-10-04 Purdue Research Foundation Multivalent RNA nanoparticles for delivery of active agents to a cell
US20080214436A1 (en) 2007-01-26 2008-09-04 City Of Hope Methods and compositions for the treatment of cancer or other diseases
US20080287383A1 (en) 2007-03-02 2008-11-20 Nastech Pharmaceutical Company Inc. Nucleic acid compounds for inhibiting erbb gene expression and uses thereof
WO2008109105A2 (en) 2007-03-06 2008-09-12 Flagship Ventures Methods and compositions for improved therapeutic effects with sirna
WO2009126933A2 (en) 2008-04-11 2009-10-15 Alnylam Pharmaceuticals, Inc. Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
EP2395085B1 (en) * 2009-02-04 2015-06-10 Sungkyunkwan University Foundation for Corporate Collaboration Small interference rna complex with increased intracellular transmission capacity
KR101141544B1 (ko) 2009-03-13 2012-05-03 한국과학기술원 에스아이알엔에이 다중 접합체 및 이의 제조방법
KR101678876B1 (ko) 2010-01-15 2016-11-23 한국과학기술원 복합 유전자를 표적하는 ｓｉＲＮＡ 다중 접합체 및 이의 제조방법
AU2011223820B2 (en) * 2010-03-01 2016-01-14 The Children's Hospital Of Philadelphia Nucleic acids for targeting multiple regions of the HCV genome
KR101340290B1 (ko) 2011-09-14 2013-12-11 한국과학기술원 유전자 표적용 ｓｉＲＮＡ 하이드로젤 및 그 제조방법
WO2013040429A1 (en) 2011-09-14 2013-03-21 Rana Therapeutics Inc. Multimeric oligonucleotide compounds
EP2895200B1 (en) 2012-09-14 2019-11-06 Translate Bio MA, Inc. Multimeric oligonucleotide compounds
CN108026527B (zh) * 2015-06-15 2022-05-10 Mpeg La有限责任公司 确定的多偶联寡核苷酸

Also Published As

Publication number Publication date
IL267806B2 (en) 2024-03-01
KR102623311B1 (ko) 2024-01-10
AU2018215684B2 (en) 2024-03-07
IL267806B1 (en) 2023-11-01
WO2018145086A1 (en) 2018-08-09
KR20240010750A (ko) 2024-01-24
IL307726A (en) 2023-12-01
JP7183167B2 (ja) 2022-12-05
IL267806A (en) 2019-09-26
CA3051480A1 (en) 2018-08-09
JP2020518552A (ja) 2020-06-25
CN110248665A (zh) 2019-09-17
EP3576752A4 (en) 2020-12-16
US20180223284A1 (en) 2018-08-09
EP3576752A1 (en) 2019-12-11
US20210380979A1 (en) 2021-12-09
US11078484B2 (en) 2021-08-03
AU2018215684A1 (en) 2019-08-01
KR20190115445A (ko) 2019-10-11
SG11201906728TA (en) 2019-08-27

Similar Documents

Publication Publication Date Title
MX2019009347A (es) Oligonucleotidos multimericos con menor eliminacion en el riñon.
WO2020097537A3 (en) Fused ring compounds
PH12019502149A1 (en) Optimized antibody compositions for treatment of ocular disorders
PH12016500904A1 (en) Anti-her2 antibody-drug conjugate
MX2022000112A (es) Anticuerpos dirigidos contra gen 3 de activacion de linfocito (lag-3).
EA201290498A1 (ru) Терапевтические полимерные наночастицы, включающие эпотилон, и способы их получения и применения
CU24567B1 (es) Derivados de piridiniltriazol sustituidos con amida útiles para tratar enfermedades renales y cardiovasculares
EA201890321A1 (ru) Молекулы антител, которые связываются с cd45
EA201991720A1 (ru) Антитела к альфа-синуклеину и их применения
WO2016100157A3 (en) 6,5-bicyclic octahydropyrrolopyridine orexin receptor antagonists
EA201591072A1 (ru) Антитела против pdgfr-бета и их применения
EA201692526A1 (ru) Замещенные [1,2,4]триазольные соединения
WO2016100162A3 (en) 5,5-bicyclic oxazole orexin receptor antagonists
EP3674314A3 (en) Apelin polypeptides
EA202091012A1 (ru) Композиции фосфорилированных тау-пептидов и их применения
CR20190561A (es) ANTICUERPOS ANTI-GARP-TGF-ß
MX2022003907A (es) Compuestos y composiciones y usos de los mismos.
EA201890449A1 (ru) Фумагиллиновые гетероциклические соединения и способы их получения и применения
MX2018002242A (es) Compuestos de piperidinobenzodiazepina con actividad antiproliferativa.
CR20190519A (es) Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo
WO2019089753A3 (en) Cd137 antibodies and pd-1 antagonists and uses thereof
EA202090414A1 (ru) Соединения и их применение
EA201692368A1 (ru) Производные, полученные из гиалуроновой кислоты и карнозина
EA201992307A1 (ru) Соединения разветвленных, терминированных полиамидов
EA201991744A1 (ru) Применение сополимеров в качестве связующих для окомкования металлсодержащих руд